{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-349133","form_type":"8-K","ticker":"AKTS","cik":"0002035832","company_name":"Aktis Oncology, Inc.","filed_at":"2026-08-13T20:04:16+00:00","discovered_at":"2026-08-13T20:05:01.001381+00:00","generated_at":"2026-08-13T20:05:04.445659+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aktis Oncology Q2 net loss $24.1M; cash $517.3M funds operations into 2029","bullets":["Net loss $24.1M for Q2 2026 vs $18.1M prior-year; interest income net of $4.8M.","Cash, equivalents, marketable securities $517.3M at June 30, 2026 vs $226.8M Dec 31, 2025.","Collaboration revenue $3.4M (Q2 2026) vs $1.6M prior-year, from Eli Lilly partnership.","R&D expenses $25.3M, up from $18.6M; G&A $7.0M vs $3.9M year-over-year.","Phase 1b trials: AKY-1189 (NECTINIUM-2) enrolling; AKY-2519 BActinium-2 to start H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-349133","json":"https://secwatch.observer/filing/0001193125-26-349133.json","markdown":"https://secwatch.observer/filing/0001193125-26-349133.md","text":"https://secwatch.observer/filing/0001193125-26-349133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526349133/0001193125-26-349133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526349133/ck0002035832-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:05:04.445659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}